Navigation Links
The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer
Date:10/5/2011

LAUSANNE, Switzerland, October 5, 2011 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today presented the 'JCA-Mauvernay Award' to Doctor Hirofumi Arakawa from the National Cancer Center Research Institute in Tokyo, for his basic research on the 'identification and characterization of p53 target genes' and to Doctor Mineo Kurokawa from the University of Tokyo, for his applied research on 'the molecular pathogenesis and therapeutic targets of hematological malignancies'. The ceremony was held during the 70th Annual Meeting of the Japanese Cancer Association (JCA) in Nagoya, Japan. This year the theme was 'Forward Strides for Cancer Research - Grounds for a Confident Future'. Professor Tetsuo Noda, President of the JCA and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group™ presented both scientists with the 2011 Award for their outstanding and innovative research.

Dr Hirofumi Arakawa works in the division of Cancer Biology at the National Cancer Center Research Institute. Since 1999, he has focused on the p53 (protein 53) tumour suppressor, which functions mainly by controlling the expression of a battery of genes involved in life and death of the cell, and which is referred to as "the guardian of the genome". Dr. Arakawa has identified, characterised and reported over 20 p53-regulated target genes.

Recently his group discovered an unusual mechanism for mitochondrial quality control, in which the p53 pathway controls mitochondrial quality by repairing or eliminating unhealthy mitochondria, suggesting that cancer cells might accumulate unhealthy mitochondria due to p53 mutations. Maintenance of healthy mitochondria prevents aging, cancer, and a variety of degenerative diseases, therefore Dr Arakawa's research offers a new approach of cancer and mitochondrial quality control, suggesting that p53 is also a guardian of mitochondria.

Dr Mineo Kurokawa works in the department of Hematology and Oncology at the Graduate School of Medicine. For 20 years, he has studied the mechanisms of malignant transformation of hematopoietic stem cells (multipotent stem cells that give rise to all blood lineages) in order to elucidate the pathogenesis of blood malignancies. He focused on the role of transcription factors associated with human leukaemia. For instance he revealed the transforming activity of EVI1, a protein frequently activated in human leukaemia and elucidated its' functions that are involved in the prevention of cell death.

Through his pursuit of the pathogenetic significance of deregulated transcription factors in leukaemia, Dr Kurokawa has consistently contributed to the understanding of a mechanistic basis of leukaemia development and the identification of novel therapeutic targets of human haematological malignancies.

"We are proud to reward these very talented and inspiring scientists for their hard work and accomplishments. The jury's decision to nominate them was unanimous," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. "We wish them a lot of luck for the future hoping their work will lead to major medical developments eventually benefiting the patients in the years to come."

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
mwagner@debiopharm.com

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com



'/>"/>
SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Circassia Acquires North American and Japanese Rights to Dopexamine
2. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
3. Japanese Cancer Association and Debiopharm Honour Japanese Research
4. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
5. GenVault Opens Japanese Subsidiary to Better Address Global Biobanking Market Growth
6. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
7. Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
8. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
9. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
10. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
11. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... OXFORD, England , December 8, 2016 ... Company, has expanded its customisable SureSeq™ NGS panel range with ... - allowing fast and cost-effective study of variants in familial ... copy number variation (CNV) detection on a single small panel ... and hotspot content. This includes all exons for LDLR ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... This CAST ... approvals for biotech crops. The authors focus on the economic effects in countries that ... approval of new biotech crops and the resultant risk of low level presence (LLP) ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... Lincoln, NE (PRWEB) , ... December 07, 2016 ... ... control systems integration, today announced that it has become a Wonderware Certified System ... Wonderware System Integrator Partner by Schneider Electric Software. , “The System Integrator Partner ...
Breaking Biology Technology:
(Date:11/29/2016)... , November 29, 2016 Nearly one billion matches ... Reading ... DERMALOG ... of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market ... Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, and Region ... to grow from USD 10.74 Billion in 2015 to reach USD 32.73 ... Continue Reading ... ...
(Date:11/19/2016)... -- Securus Technologies, a leading provider of civil and ... and monitoring, announced today that it has offered a ... independent technology judge determine who has the largest and ... calling platform, and the best customer service. ... what we do – which clearly is not the ...
Breaking Biology News(10 mins):